Article ID Journal Published Year Pages File Type
10852753 Biologicals 2011 4 Pages PDF
Abstract
The present contribution illustrates the rationale for and general principles of the clinical programs used in the development of SBPs, taking the example of the three biosimilar products developed and marketed in Europe by Sandoz, namely growth hormone (Omnitrope®, the first ever EU biosimilar approval), erythropoietin α (Binocrit®), and filgrastim (Zarzio®).
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Biochemistry, Genetics and Molecular Biology (General)
Preview
Clinical programs in the development of similar biotherapeutic products: Rationale and general principles
Authors
,